☆ 4.7 Review

The Effectiveness and Tolerability of Atropine Eye Drops for Myopia Control in Non-Asian Regions

JOURNAL OF CLINICAL MEDICINE (2023)

Related references

Note: Only part of the references are listed.

Article Ophthalmology

Symptoms and ocular findings associated with administration of 0.01% atropine in young adults

Ben Cyphers et al.

Summary: This study investigated the effects of nightly administration of 0.01% atropine eye drops on visual acuity, accommodation performance, and side effects. The results showed that there were no clinically meaningful symptoms after using the eye drops for 1 week, indicating that patients would be willing to continue using the drops to delay the onset of myopia.

CLINICAL AND EXPERIMENTAL OPTOMETRY (2023)

Add to Collection

Article Ophthalmology

Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout Phase 3 Report

Jason C. Yam et al.

Summary: The study aimed to compare the efficacy of different concentrations of atropine treatment in the third year, evaluate the efficacy of continued treatment over 3 years, and investigate the rebound phenomenon after cessation of treatment. The results showed that continued treatment achieved better outcomes in terms of myopia progression and axial elongation compared to the washout regimen across all concentrations. The optimal concentration for 3-year treatment in Chinese children was 0.05% atropine.

OPHTHALMOLOGY (2022)

Add to Collection

Article Ophthalmology

Efficacy and Safety of 8 Atropine Concentrations for Myopia Control in Children A Network Meta-Analysis

Ahnul Ha et al.

Summary: This study compares the efficacy and safety of different concentrations of atropine for myopia control through network meta-analysis. The results show that the 1%, 0.5%, and 0.05% concentrations of atropine are ranked as the most beneficial for myopia control in terms of yearly changes in refraction and axial length. The 0.05% concentration of atropine is ranked as the most beneficial for overall myopia progression. The risk of adverse effects tends to increase with higher atropine concentrations.

OPHTHALMOLOGY (2022)

Add to Collection

Article Ophthalmology

Low-concentration atropine eyedrops for myopia control in a multi-racial cohort of Australian children: A randomised clinical trial

Samantha Sze-Yee Lee et al.

Summary: This study aimed to test the safety and efficacy of 0.01% atropine eyedrops as a myopia-control approach in Australian children. The results showed that the atropine group had a smaller change in myopia compared to the placebo group at 12 months, but the difference was not significant at 24 months. Additionally, the atropine group also experienced a decrease in accommodative amplitude and pupillary light response.

CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2022)

Add to Collection

Article Ophthalmology

Myopia progression and axial elongation in Spanish children: Efficacy of atropine 0.01% eye-drops

M. Moriche-Carretero et al.

Summary: Spanish children showed a low rate of myopia progression, with significant effects in slowing down myopia and axial elongation when using 0.01% atropine eye drops. The treatment group had a 32% reduction in myopia progression, with a higher percentage of progressors in the control group.

JOURNAL FRANCAIS D OPHTALMOLOGIE (2021)

Add to Collection

Article Ophthalmology

Side effects of topical atropine 0.05% compared to 0.01% for myopia control in German school children: a pilot study

Lutz Joachimsen et al.

Summary: When Caucasian children were treated with 0.05% atropine, stronger and more relevant side effects were observed compared to 0.01%, including visual impairment and decreased accommodation amplitude. These findings suggest that the higher concentration of atropine may compromise acceptance and compliance in young Caucasian children with progressive myopia.

INTERNATIONAL OPHTHALMOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

A multicenter Spanish study of atropine 0.01% in childhood myopia progression

Ines Perez-Flores et al.

Summary: The study evaluated the efficacy and safety of 0.01% atropine eye drops for myopia control in a pediatric Spanish cohort, finding it to be effective and safe. The research also showed an inverse correlation between myopia progression and axial length elongation, with no identified specific risk factors for progression.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Medicine, General & Internal

The Effect of Long-Term Low-Dose Atropine on Refractive Progression in Myopic Australian School Children

William Myles et al.

Summary: Low-dose atropine can slow the progression of myopia in children, especially in the 'slow' progression group. However, rebound occurred in three-quarters of eyes after cessation of atropine. Adverse effects were observed in 69% of patients, with dilated pupils being more common in children with blue eyes.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Article Ophthalmology

A retrospective analysis of the therapeutic effects of 0.01% atropine on axial length growth in children in a real-life clinical setting

Hakan Kaymak et al.

Summary: The study found that 0.01% atropine eye drops have a certain effect on slowing down myopia progression in children, especially in inhibiting axial length growth, but the impact on myopic refraction is not significant.

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2021)

Add to Collection

Article Ophthalmology

IMI Prevention of Myopia and Its Progression

Jost B. Jonas et al.

Summary: The prevalence of myopia is increasing in East and Southeast Asia, with strategies needed to reduce its progression. Encouraging outdoor activities and using low-dose atropine eye drops are beneficial measures for reducing myopia development. Individual risk-to-benefit ratios need to be considered for different treatment options based on age, health, and lifestyle.

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2021)

Add to Collection

Article Ophthalmology

Low-dose (0.01%) atropine eye-drops to reduce progression of myopia in children: a multicentre placebo-controlled randomised trial in the UK (CHAMP-UK)-study protocol

Augusto Azuara-Blanco et al.

BRITISH JOURNAL OF OPHTHALMOLOGY (2020)

Add to Collection

Article Ophthalmology

A 3-year follow-up study of atropine treatment for progressive myopia in Europeans

Jan Roelof Polling et al.

EYE (2020)

Add to Collection

Article Ophthalmology

Low-Concentration Atropine for Myopia Progression (LAMP) Study A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control

Jason C. Yam et al.

OPHTHALMOLOGY (2019)

Add to Collection

Article Ophthalmology

Efficacy of atropine 0.01% for the treatment of childhood myopia in European patients

Matteo Sacchi et al.

ACTA OPHTHALMOLOGICA (2019)

Add to Collection

Article Ophthalmology

Prevention and Management of Myopia and Myopic Pathology

Seang-Mei Saw et al.

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2019)

Add to Collection

Article Ophthalmology

The epidemics of myopia: Aetiology and prevention

Ian G. Morgan et al.

PROGRESS IN RETINAL AND EYE RESEARCH (2018)

Add to Collection

Article Multidisciplinary Sciences

Incidence and progression of myopia and associated factors in urban school children in Delhi: The North India Myopia Study (NIM Study)

Rohit Saxena et al.

PLOS ONE (2017)

Add to Collection

Article Ophthalmology

The acceptability and visual impact of 0.01% atropine in a Caucasian population

James Loughman et al.

BRITISH JOURNAL OF OPHTHALMOLOGY (2016)

Add to Collection

Article Ophthalmology

Effectiveness study of atropine for progressive myopia in Europeans

J. R. Polling et al.

EYE (2016)

Add to Collection

Article Ophthalmology

Age of onset of myopia predicts risk of high myopia in later childhood in myopic Singapore children

Sharon Y. L. Chua et al.

OPHTHALMIC AND PHYSIOLOGICAL OPTICS (2016)

Add to Collection

Article Ophthalmology

Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2 Myopia Control with Atropine 0.01% Eyedrops

Audrey Chia et al.

OPHTHALMOLOGY (2016)

Add to Collection

Article Ophthalmology

Efficacy Comparison of 16 Interventions for Myopia Control in Children A Network Meta-analysis

Jinhai Huang et al.

OPHTHALMOLOGY (2016)

Add to Collection

Article Ophthalmology

Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050

Brien A. Holden et al.

OPHTHALMOLOGY (2016)

Add to Collection

Article Ophthalmology

Updates of pathologic myopia

Kyoko Ohno-Matsui et al.

PROGRESS IN RETINAL AND EYE RESEARCH (2016)

Add to Collection

Article Public, Environmental & Occupational Health

Prevalence of refractive error in Europe: the European Eye Epidemiology (E3) Consortium

Katie M. Williams et al.

EUROPEAN JOURNAL OF EPIDEMIOLOGY (2015)

Add to Collection

Article Ophthalmology

Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2)

Audrey Chia et al.

OPHTHALMOLOGY (2012)

Add to Collection

Article Ophthalmology

Predicted reduction in high myopia for various degrees of myopia control

Noel A. Brennan

Contact Lens & Anterior Eye (2012)

Add to Collection

Review Ophthalmology

Myopia and associated pathological complications

SM Saw et al.

OPHTHALMIC AND PHYSIOLOGICAL OPTICS (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.